Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: Combined analysis of calgb 9342 and 9840

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 632-638

  Lichtman, S M ^a   Hurria, A ^b   Cirrincione, C T ^c   Seidman, A D ^a   Winer, E ^d   Hudis, C ^a   Cohen, H J ^e   Muss, H B ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Population Sciences ^*  (United States)

^c CALGB Statistical Center   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer; Elderly; Geriatric oncology; Geriatrics; Neurotoxicity; Paclitaxel

Indexed keywords

BILIRUBIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; AGING; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; BREAST CANCER; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CEREBELLUM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; EYE TOXICITY; FEMALE; FUNCTIONAL STATUS; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; METASTASIS POTENTIAL; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SENSORY DYSFUNCTION; SIDE EFFECT; TREATMENT RESPONSE;

EID: 84857526399     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr297     Document Type: Article

References (20)

1. Klepin H, Mohile S, Hurria A. Geriatric assessment in older patients with breast cancer. J Natl Compr Canc Netw 2009; 7: 226-236.
2. Crivellari D, Aapro M, Leonard R et al. Breast cancer in the elderly. J Clin Oncol 2007; 25: 1882-1890.
3. Bouchardy C, Rapiti E, Blagojevic S et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007; 25: 1858-1869.
4. Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 2009; 85: 103-107.
5. Dixon DO, Neilan B, Jones S et al. Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295-305.
6. Muss HB, Berry DA, Cirrincione C et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 2007; 25: 3699-3704.
7. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
8. Seidman AD, Berry D, Cirrincione C et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26: 1642-1649.
9. Winer EP, Berry DA, Woolf S et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 2004; 22: 2061-2068.
10. Agresti A, Mehta CR, Patel NR. Exact inference for contingency tables with ordered categories. J Am Stat Assoc 1990; 85: 453-458.
11. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley 1989.
12. Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 34: 187-220.
13. Lichtman SM, Hollis D, Miller AA et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006; 24: 1846-1851.
14. Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293: 1073-1081.
15. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
16. Del Mastro L, Perrone F, Repetto L et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005; 16: 253-258.
17. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.
18. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993; 107-115.
19. Kumar A, Soares HP, Balducci L, Djulbegovic B. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 2007; 25: 1272-1276.
20. Hilpert F, du Bois A, Greimel ER et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or = 70 years with advanced ovarian cancer-a study by the AGO OVAR Germany. Ann Oncol 2007; 18: 282-287.